Dermatology Times has published evidence-based safety guidelines covering cosmetic dermatology in pregnancy and lactation, giving clinicians a structured framework for a patient population that cosmetic practices see regularly but often manage inconsistently.

The guidance addresses a persistent gap in aesthetic practice. Pregnant and lactating patients frequently request cosmetic procedures, yet much of the safety literature for injectables, energy-based devices and topical cosmeceuticals was never designed to capture obstetric outcomes. Clinicians have historically relied on case reports, manufacturer labeling and expert consensus rather than systematic evidence review — the situation these guidelines aim to correct.

The timing matters. Delayed childbearing means aesthetic practices are treating more patients who are pregnant, planning pregnancy or breastfeeding than was the case a generation ago, and questions about which treatments can safely continue now arise routinely in consultation rather than exceptional cases.

Why an evidence-based framework was needed

The core clinical problem is asymmetry of evidence. Cosmetic procedures are typically studied in non-pregnant adults, so safety in pregnancy is inferred rather than demonstrated. That leaves dermatologists weighing:

• The absence of documented harm for many common procedures
• The absence of adequate controlled data proving safety
• Medication labeling that often reflects legal caution more than demonstrated risk
• Patient demand that continues regardless of the evidence gaps

An evidence-based approach forces each treatment decision to be anchored to the best available class of data — systematic reviews, cohort studies, case series or expert opinion — rather than to habit or manufacturer defaults.

What the guidance covers

The guidelines span the main categories of cosmetic dermatology: topical agents and cosmeceuticals, injectable neuromodulators and fillers, and energy-based devices. For each category, the framework evaluates what the reproductive-safety evidence actually supports and where the uncertainty remains too large to justify treatment during pregnancy or lactation.

The general principle that runs through evidence-based guidance in this field is conservative: elective aesthetic procedures are, by definition, not medically necessary, so the risk-benefit calculation shifts. A treatment with even a small theoretical risk and no therapeutic urgency is difficult to justify when deferral until the postpartum period is an available option. Where evidence supports safety — as it does for certain topical agents during lactation, when systemic absorption is minimal — the guidance allows clinicians to reassure patients rather than refuse them outright.

Why the distinction between pregnancy and lactation matters

The two physiological states carry different risk profiles, and the guidance treats them separately. During pregnancy, the concern is placental transfer and teratogenicity. During lactation, the concern shifts to drug transfer into breast milk and exposure to the infant — a different pharmacokinetic question that sometimes permits treatments that would be deferred in pregnancy.

This distinction has practical consequences for consultation flow. A patient who deferred neuromodulator treatment through pregnancy may be a candidate earlier in the postpartum period than she assumes, or may need to defer longer depending on the agent and the feeding situation. Structured guidance replaces ad hoc judgment on these boundaries.

The counseling dimension

Beyond the procedural checklist, the guidelines function as a communication tool. Patients presenting for cosmetic consultation are often not yet aware of a pregnancy, or may not disclose lactation unprompted, which makes routine screening a standard part of the aesthetic intake for women of reproductive age. When deferral is recommended, an evidence-based reference supports the conversation and sets expectations for when treatment can resume.

For practices, the framework also has a documentation function: recording the evidence class behind each treatment decision during pregnancy or lactation strengthens the clinical record where the margin for error is smallest.

How widely these guidelines reshape everyday prescribing habits will depend on their integration into practice protocols and patient intake forms — but they give dermatologists a defensible, evidence-graded starting point for a question that cosmetic practices face with increasing frequency.

Editor's note: The underlying Dermatology Times guidance should be consulted directly for agent-specific recommendations.